Document is current
Any future updates will be listed below
-
Authors
Miyauchi, Sayuri https://orcid.org/0009-0000-8439-7751
Roy, Souvick
Boutros, Nathalie
Sharabi, Andrew B. https://orcid.org/0000-0003-2075-1197
- License Information
-
More Information
Article History
Received: 5 September 2024
Revised: 10 January 2025
Accepted: 30 January 2025
First Online: 12 March 2025
Competing interests
: ABS reports research funding and honoraria from Pfizer and Varian Medical Systems, consultant fees from Astrazeneca and Primmune. ABS is the scientific founder and has an equity interest in Toragen Inc. that could potentially benefit from the research results. ABS has an equity interest in Advanced B-cell Therapeutics outside submitted work. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. All other authors report no competing interests.
